Archives 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 August 11, 2022 Result of Broker Option / PDMR Dealings Read More August 04, 2022 INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022 Read More August 03, 2022 Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m Read More July 11, 2022 FDA confirms response date for Type C Meeting as 29th August 2022 Read More July 07, 2022 Initiation of research Read More June 28, 2022 2022 Result of ANNUAL GENERAL MEETING – all resolutions passed Read More June 27, 2022 Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients Read More June 21, 2022 Lanstead Capital Investors LP share holding update Read More June 01, 2022 Notice of AGM & Annual Report & Accounts Read More May 25, 2022 FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2021 Read More May 04, 2022 UPDATE on LUPUZOR™ – POSITIVE PROGRESS to PHASE 3 with AVION Read More April 13, 2022 UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More 123…18
August 04, 2022 INVESTOR PRESENTATION Via Investor Meet Company Platform | 12 midday (BST) | 4 August 2022 Read More
August 03, 2022 Subscription and Placing to raise £1.1 million; Sharing Agreement; to progress product portfolio. Broker Option to raise up to £1.3m Read More
June 27, 2022 Avion seeks final regulatory guidance as it prepares for the start of the international Phase 3 trial of Lupuzor™ in Lupus patients Read More
April 13, 2022 UPDATE on P140 (LUPUZOR™) clinical progress. Data confirms positive readout from P140 PK study. Read More
